Human immunoglobulin(pH4)(Boya Bio-pharmaceutical Group Co., Ltd.)

Primary purpose: To evaluate the efficacy of intravenous human immunoglobulin (10%) in the treatment of primary immune thrombocytopenia (ITP) in adults and adolescents (≥12 years old), and to evaluate the efficacy of intravenous human immunoglobulin (10%) produced by Boya Biopharmaceutical Group Co., Ltd. by analyzing the proportion of subjects with platelet counts ≥30×109/L and increased to more than 2 times the baseline within 7 days after the first infusion. Secondary purpose: 1) Observe and evaluate the efficacy through other secondary efficacy indicators; 2) Observe and evaluate safety.